Prevencio Announces Highly Accurate, AI-driven Blood Test with High Sensitivity (hs) Cardiac Troponin for the Diagnosis of Heart Disease
Prevencio, Inc. today announces data confirming the high accuracy of its AI-driven, multiple-protein HART CADhs test, a biomarker clinical/proteomic panel inclusive of high sensitivity cardiac troponin for the diagnosis of obstructive Coronary Artery Disease (CAD), also known as heart disease.
Prevencio, Inc. today announces data confirming the high accuracy of its AI-driven, multiple-protein HART CADhs test, a biomarker clinical/proteomic panel inclusive of high sensitivity cardiac troponin for the diagnosis of obstructive Coronary Artery Disease (CAD), also known as heart disease. Researchers highlighted that these important findings, presented November 18 at the 2019 American Heart Association (AHA) Scientific Sessions in Philadelphia, performed with high accuracy on two different patient groups from Massachusetts General Hospital (MGH) and The University Heart Center, Hamburg, Germany.
HART CADhs data from 1,152 patients were presented as “Derivation and External Validation of a High Sensitivity Troponin Based Proteomic Model to Predict the Presence of Obstructive Coronary Artery Disease: Value in the Troponin Indeterminant Zone.” In this study, HART CADhs test was developed from 636 patient blood samples from MGH. The HART CADhs test was then internally validated on 275 different patients from MGH and finally was positively validated on 241 patients who presented to the ED with heart attack suspicion at The University Heart Center (UHC), Hamburg, Germany. Notably, performance of HART CADhs test was strong among UHC ED patients in the troponin indeterminant zone (patients who were neither rule-in nor rule-out for heart attack, but there were concerns for heart artery obstruction which could cause a heart attack in the near-term).
Commenting on the study, Dr. James Januzzi said, “We feel these data are significant and demonstrate high accuracy for chest pain patients presenting to the ED. These patients need timely and accurate assessment, and we are hopeful this blood test will help both patients and clinicians.” Januzzi added, “The artificial intelligence, multi-protein approach is novel in cardiology, and our data demonstrates the power of the HART platform that Prevencio has developed.”
Rhonda Rhyne, Prevencio’s Chief Executive Officer, added, “With more than 8 million chest pain patients presenting annually to U.S. emergency departments alone, it has been clearly established that there is clinical unmet need for better techniques to triage ED chest pain patients. The data presented from two separate patient groups from different parts of the world not only validates that our HART CADhs blood test accurately addresses this unmet need, but further substantiates that Prevencio’s Artificial Intelligence Platform can produce highly accurate tests with clinical value.” Rhyne concluded, “We are very grateful for our ongoing collaboration with Dr. Januzzi, MGH researchers, Drs. Dirk Westermann and Johannes Neumann at Hamburg’s University Heart Center, and our lab partner, Myriad RBM.”
Powered by AI, Prevencio is revolutionizing blood tests for cardiovascular disease. Employing this novel approach, the company has developed six blood tests to-date that significantly improve diagnoses for a variety of heart and blood vessel-related complications.
These tests are:
- HART CAD™ / CADhs™ – obstructive coronary artery disease diagnosis
- HART CVE™ – 1-year risk of heart attack, stroke or cardiac death
- HART PAD™ – peripheral artery disease diagnosis
- HART AS™ – aortic valve stenosis diagnosis
- HART AMP™ – risk of amputation
- HART AKI™ – risk of acute kidney injury
HART test results have been presented at leading cardiovascular meetings—(European Society of Cardiology Congress Scientific Sessions – 2016 & 2018, American College of Cardiology Scientific Sessions – 2017, 2018 & 2019, American Heart Association Scientific Sessions – 2017, 2018 & 2019, and American Diabetes Association Scientific Sessions – 2018) and published in top-tier cardiology journals—(Journal of American College of Cardiology – March 2017, American Journal of Cardiology – July 2017, Open Heart – November 2018 and Clinical Cardiology – June 2018 & January 2019).
About Prevencio, Inc.:
Prevencio's value proposition is "Preventing the Preventable” — That is, preventing unnecessary procedures, related side effects, and expense, as well as improving patient outcomes and clinical trials through more accurate blood tests for Cardiovascular Disease conditions. Prevencio utilizes Machine Learning (Artificial Intelligence) + Multi-Proteomic Biomarkers + Proprietary Algorithms to deliver cardiovascular diagnostic & prognostic tests that are significantly more accurate than standard-of-care stress tests, individual biomarkers, genetic markers and clinical risk scores. The company is headquartered in Kirkland, Washington. For additional information, visit www.PrevencioMed.com. Prevencio—Preventing the Preventable.™
Forward-Looking (Safe Harbor) Statement:
Except for historical and factual information contained herein, this press release contains forward-looking statements, such as market need, acceptance, size, and penetration rates, the accuracy of which is necessarily subject to uncertainties and risks including the Company’s sole dependence on HART technology and various uncertainties characteristic of development-stage companies. The Company does not undertake to update the disclosures contained in this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191119005375/en/